新闻称，英格兰国家卫生服务（NHS）患必威手机APP者将受益于新的3.4亿英镑（4.73亿美元； 3.98亿欧元），每年创新药品基金（IMF），最初是由保守党政府在其2019年重新选举中承诺的宣言 - 在整个领域的利益相关者受到热烈欢迎。期望该基金将对最具创新性的新疗法（包括针对孤儿和罕见疾病）提供快速通道。但是，由于该计划的细节仍然很少，因此目前尚不清楚患者如何以及何时从该计划中受益。
NHS英格兰于7月21日表示，IMF将与现有的癌症药物基金（CDF）一起实施，并将“支持NHS，以快速训练患者获得可以表现出可观的临床承诺的治疗方法，但在其临床方面仍然存在很大的不确定性以及成本效益，因此纳税人的长期价值”。根据NHS England的说法，CDF还受益于3.4亿英镑的年度预算，新基金的建立将意味着每年将提供总共6.8亿英镑的环形资金，以加快获得新治疗的机会。
On the face of it, the IMF is undoubtedly good news for patients. According to Health and Social Care Secretary Sajid Javid, the new Fund will extend the CDF model to cover a greater number of treatments. In practice, this is likely to mean that the IMF will function as a conditional reimbursement scheme, enabling selected drugs to be covered in the NHS while further evidence is gathered on their effectiveness, prior to a final evaluation by the National Institute for Health and Care Excellence (NICE). This model, which has been used by the CDF since 2016, has proved durable and has won support from patient advocates such as Cancer Research UK, despite initial opposition from industry.
基于IMF基于现有的CDF模型，还将确保新基金避免了癌症基金在2011年面临的大部分争议。然后，CDF的开放性本质使其容易受到批评被用来规避良好的评估过程 - 这是CDF对2016年大修的批评。国际货币基金组织的推出也具有解决CDF上另一项关键批评的优势，即癌症基金“特权”肿瘤学比其他疗法领域。通过为最有前途的治疗提供专门的资金，无论需要治疗如何，新的国际货币基金组织都可以使更多患者能够从更快地使用新药物中受益。
In addition, the IMF could help to address some of the regional inequalities that blight the UK health system. In Scotland, patients have since 2014 been able to access funding for innovative ultra-orphan, orphan and end-of-life treatments via a dedicated New Medicines Fund, and in this regard the IMF may bring similar benefits for patients suffering from such conditions in England. Yet at the same time, other inequities will persist: such funding will still not be available to residents of Wales or Northern Ireland, and the separate cancer fund will remain open only to patients in England.
Furthermore, despite assurances that the new IMF will mimic the existing CDF, NHS England has not yet published details of how the Fund will work in practice. It is not clear how the NHS will select products for funding via the scheme, nor how the IMF will interact with NICE. Depending on the criteria for admission to the scheme, some products are likely to remain ineligible – and with a limited funding pool available, some patients will inevitably be disappointed.
目前，英国制药行业（ABPI）的协会和其他人欢迎该基金，这是“改善NHS患者获得新药物的重要一步”。随着2021年晚些时候的利益相关者咨询，制造商可能不再等待，以了解IMF的真正一步。
IQVIA Pharma Pricing & Reimbursement (PPR) draws on decades of experience in the market access space to bring you the latest global developments in pricing and reimbursement. With access to IQVIA’s network of local offices, and extensive contacts within government and industry, the PPR service offers timely news and articles alongside comprehensive guides to P&R regulations around the world. Fore more information about IQVIA Pharma Pricing & Reimbursement, contact ushere。